Real Options Analysis for Biotech R&D Decisions
Quantify the value of strategic flexibility in biotech R&D with binomial lattices, Longstaff-Schwartz Monte Carlo, compound options, Greeks, exercise boundaries, and option-value decomposition.
Decision questions
What this solution is built to answer.
Should the company invest now, wait for more evidence, expand, narrow, or abandon?
How much value comes from future managerial flexibility rather than the static plan?
Which assets need real-options analysis and which should stay in standard risk-adjusted valuation?
How does volatility, time to decision, and investment cost change the action threshold?
Science and method
What can change the model or gate.
Real-options fit check by development stage: preclinical through Phase II as critical, Phase III as selective, approved assets usually skipped.
Binomial and trinomial lattices for stage-gated managerial decisions.
Longstaff-Schwartz Monte Carlo for American-style option decisions.
Compound option modeling for multi-stage development chains.
Exercise boundary, volatility surface, Greeks, time decay, and method-comparison outputs.
Method and decision gates
How the case is computed and reviewed.
| Workflow | Role | Artifacts |
|---|---|---|
| valuation-enterprise-workflow | Runs the real-options analysis suite per applicable asset | VALUATION__ROA, decision tree, lattice, boundary, volatility, decomposition |
| portfolio-optimization | Connects optionality to capital allocation | Efficient frontier, scenario stress, resource allocation, board dossier |
Evidence inputs
Supporting evidence, rights and decision inputs.
Decision record
What remains available for review.
Deliverables
Real-options fit matrix across assets.
WAIT vs EXERCISE decision maps.
Option value decomposition from static NPV to total strategic value.
Method-comparison table across binomial, Monte Carlo, and related methods.
Proof points
The enterprise valuation workflow skips real-options analysis for assets with little meaningful R&D flexibility.
Real-options analysis sits alongside baseline valuation so the underlying value case remains auditable.
Outputs are file artifacts with decision maps, boundaries, and decomposition tables.
Limits and review conditions
What this result does not establish.
Real-options methods are useful only when the team has a genuine future choice and defensible volatility and timing assumptions.
FAQ
Common evaluation questions.
When is ROA appropriate in biotech?
Real-options analysis is most useful when future decisions can change the path of the asset: defer, expand, abandon, stage, switch indications, or preserve optionality while uncertainty resolves.
Does real-options analysis replace rNPV?
ARiDA treats risk-adjusted NPV as the baseline and real-options analysis as the layer that quantifies decision flexibility around that baseline.
Related solutions
Biotech Valuation
Connect scientific evidence and uncertainty to PoS, rNPV, option value and the asset or portfolio decision under review.
Portfolio Optimization
Prioritize a biopharma portfolio with value modeling, correlation, downside risk, stage-gate logic and explicit scenarios.
Clinical Trial Intelligence
Analyze trial landscapes, protocol patterns, endpoints, enrollment signals, sponsor behavior, recent registry changes, and historical AACT structure.
Related reading
Build a biotech valuation case that exposes its science
A credible valuation connects scientific support, uncertainty and commercial assumptions to the value distribution.
Why committee outputs need a computation record
The memo should summarize an inspectable case, not substitute for one.
Design scientific decision systems around methods, not prompts
Stable calculators, evidence contracts and explicit gates should carry repeatable parts of the work.